Metabolism negotiates cell-endogenous requirements of energy, nutrients and building blocks with the immediate environment to enable various processes, including growth and differentiation. While there is an increasing number of examples of crosstalk between metabolism and chromatin, few involve uptake of exogenous metabolites. Solute carriers (SLCs) represent the largest group of transporters in the human genome and are responsible for the transport of a wide variety of substrates, including nutrients and metabolites. We aimed to investigate the possible involvement of SLC-mediated solutes uptake and cellular metabolism in regulating cellular epigenetic states. Here, we perform a CRISPR–Cas9 transporter-focused genetic screen and a metabolic compound library screen for the regulation of BRD4-dependent chromatin states in human myeloid leukaemia cells. Intersection of the two orthogonal approaches reveal that loss of transporters involved with purine transport or inhibition of de novo purine synthesis lead to dysfunction of BRD4-dependent transcriptional regulation. Through mechanistic characterization of the metabolic circuitry, we elucidate the convergence of SLC-mediated purine uptake and de novo purine synthesis on BRD4-chromatin occupancy. Moreover, adenine-related metabolite supplementation effectively restores BRD4 functionality on purine impairment. Our study highlights the specific role of purine/adenine metabolism in modulating BRD4-dependent epigenetic states.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science https://doi.org/10.1126/science.aal2380 (2017).
Sharma, S., Kelly, T. K. & Jones, P. A. Epigenetics in cancer. Carcinogenesis 31, 27–36 (2010).
Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463 (2004).
Ulrey, C. L., Liu, L., Andrews, L. G. & Tollefsbol, T. O. The impact of metabolism on DNA methylation. Hum. Mol. Genet. 14, R139–R147 (2005).
Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074–1080 (2001).
Cesar-Razquin, A. et al. A call for systematic research on solute carriers. Cell 162, 478–487 (2015).
Hediger, M. A. et al. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflug. Arch. 447, 465–468 (2004).
Zhang, Y., Zhang, Y., Sun, K., Meng, Z. & Chen, L. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J. Mol. Cell. Biol. 11, 1–13 (2019).
Rebsamen, M. et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 519, 477–481 (2015).
Song, W., Li, D., Tao, L., Luo, Q. & Chen, L. Solute carrier transporters: the metabolic gatekeepers of immune cells. Acta Pharm. Sin. B. 10, 61–78 (2020).
Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).
Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011).
Sdelci, S. et al. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nat. Chem. Biol. 12, 504–510 (2016).
Sdelci, S. et al. MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nat. Genet. 51, 990–998 (2019).
Girardi, E. et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nat. Chem. Biol. https://doi.org/10.1038/s41589-020-0483-3 (2020).
Young, J. D., Yao, S. Y., Baldwin, J. M., Cass, C. E. & Baldwin, S. A. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol. Asp. Med. 34, 529–547 (2013).
Meixner, E. et al. A substrate-based ontology for human solute carriers. Mol. Syst. Biol. 16, e9652 (2020).
Tandio, D., Vilas, G. & Hammond, J. R. Bidirectional transport of 2-chloroadenosine by equilibrative nucleoside transporter 4 (hENT4): evidence for allosteric kinetics at acidic pH. Sci. Rep. 9, 13555 (2019).
Ishida, N. & Kawakita, M. Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). Pflug. Arch. 447, 768–775 (2004).
Ahuja, S. & Whorton, M. R. Structural basis for mammalian nucleotide sugar transport. eLife https://doi.org/10.7554/eLife.45221 (2019).
Matsuyama, R. et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J. Cancer 119, 406–413 (2006).
Badagnani, I. et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 5, 157–165 (2005).
Ho, H. T., Xia, L. & Wang, J. Residue Ile89 in human plasma membrane monoamine transporter influences its organic cation transport activity and sensitivity to inhibition by dilazep. Biochem. Pharmacol. 84, 383–390 (2012).
Cara, C. J. et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci. Monit. 10, RA247–RA254 (2004).
Kamynina, E. et al. Arsenic trioxide targets MTHFD1 and SUMO-dependent nuclear de novo thymidylate biosynthesis. Proc. Natl Acad. Sci. USA 114, E2319–E2326 (2017).
Liu, Y. C. et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS ONE 3, e2722 (2008).
Donati, B., Lorenzini, E. & Ciarrocchi, A. BRD4 and cancer: going beyond transcriptional regulation. Mol. Cancer 17, 164 (2018).
Donato, E. et al. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors. Leukemia 31, 479–490 (2017).
Nigam, S. K. What do drug transporters really do? Nat. Rev. Drug Disco. 14, 29–44 (2015).
Foucquier, J. & Guedj, M. Analysis of drug combinations: current methodological landscape. Pharm. Res Perspect. 3, e00149 (2015).
Di Veroli, G. Y. et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866–2868 (2016).
Wang, C. et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem. Pharmacol. 86, 1531–1540 (2013).
Winter, G. E. et al. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Mol. Cell 67, 5–18.e19 (2017).
Shimazu, T. et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211–214 (2013).
Mentch, S. J. et al. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab. 22, 861–873 (2015).
Menga, A. et al. SLC25A26 overexpression impairs cell function via mtDNA hypermethylation and rewiring of methyl metabolism. FEBS J. 284, 967–984 (2017).
Morciano, P. et al. A conserved role for the mitochondrial citrate transporter Sea/SLC25A1 in the maintenance of chromosome integrity. Hum. Mol. Genet. 18, 4180–4188 (2009).
Di Virgilio, F. Purines, purinergic receptors, and cancer. Cancer Res. 72, 5441–5447 (2012).
Di Virgilio, F. & Adinolfi, E. Extracellular purines, purinergic receptors and tumor growth. Oncogene 36, 293–303 (2017).
Pellegatti, P. et al. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3, e2599 (2008).
Pastor-Anglada, M. & Perez-Torras, S. Emerging roles of nucleoside transporters. Front Pharm. 9, 606 (2018).
Yin, J. et al. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol. 9, 1697 (2018).
Hasan, N. & Ahuja, N. The emerging roles of ATP-dependent chromatin remodeling complexes in pancreatic cancer. Cancers https://doi.org/10.3390/cancers11121859 (2019).
Hargreaves, D. C. & Crabtree, G. R. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 21, 396–420 (2011).
Conrad, R. J. et al. The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes. Mol. Cell 67, 1001–1012.e1006 (2017).
Kole, H. K., Abdel-Ghany, M. & Racker, E. Specific dephosphorylation of phosphoproteins by protein-serine and -tyrosine kinases. Proc. Natl Acad. Sci. USA 85, 5849–5853 (1988).
Wu, S. Y., Lee, A. Y., Lai, H. T., Zhang, H. & Chiang, C. M. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 49, 843–857 (2013).
Wang, R., Yang, J. F., Ho, F., Robertson, E. S. & You, J. Bromodomain-containing protein BRD4 Is hyperphosphorylated in mitosis. Cancers https://doi.org/10.3390/cancers12061637 (2020).
Demine, S., Renard, P. & Arnould, T. Mitochondrial uncoupling: a key controller of biological processes in physiology and diseases. Cells https://doi.org/10.3390/cells8080795 (2019).
Raux, B. et al. Exploring selective inhibition of the first bromodomain of the human bromodomain and extra-terminal domain (BET) proteins. J. Med. Chem. 59, 1634–1641 (2016).
Noguchi-Yachide, T., Sakai, T., Hashimoto, Y. & Yamaguchi, T. Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors. Bioorg. Med. Chem. 23, 953–959 (2015).
Picaud, S. et al. 9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J. Med. Chem. 58, 2718–2736 (2015).
Pawar, A., Gollavilli, P. N., Wang, S. & Asangani, I. A. Resistance to BET inhibitor leads to alternative therapeutic vulnerabilities in castration-resistant prostate cancer. Cell Rep. 22, 2236–2245 (2018).
Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525, 543–547 (2015).
Cross, B. C. et al. Increasing the performance of pooled CRISPR-Cas9 drop-out screening. Sci. Rep. 6, 31782 (2016).
Montague, T. G., Cruz, J. M., Gagnon, J. A., Church, G. M. & Valen, E. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 42, W401–W407 (2014).
Bigenzahn, J. W. et al. LZTR1 is a regulator of RAS ubiquitination and signaling. Science 362, 1171–1177 (2018).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Sergushichev, A. A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. Preprint at bioRxiv https://doi.org/10.1101/060012 (2016).
Pemovska, T. et al. Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. 62nd ASH Annual Meeting and Exposition. abstr. 3374 https://ash.confex.com/ash/2020/webprogram/Paper134769.html (2020).
Kamentsky, L. et al. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics 27, 1179–1180 (2011).
Schick, S. et al. Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers. Nat. Genet. 51, 1399–1410 (2019).
Jiang, H., Lei, R., Ding, S. W. & Zhu, S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinf. 15, 182 (2014).
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
We thank all members of the Superti-Furga and Kubicek laboratories for discussions, feedback and reagents, the Platform Austria for Chemical Biology (PLACEBO) for metabolic compound library plating, the Proteomics and Metabolomics Facility for metabolomics analyses and the BSF for next-generation sequencing. In particular, we thank A. Casiraghi for providing valuable feedback. CeMM and the Superti-Furga and Kubicek laboratories are supported by the Austrian Academy of Sciences. We acknowledge receipt of third-party funds from the Austrian Science Fund (grant nos. FWF SFB F4711 to F.K., J.W.B. and G.S-F. and I2192-B22 ERASE to V.S.), the European Research Council (grant no. ERC AdG 695214 GameofGates to K-C.L., E.G., A.B., U.G. and G.S-F.), the European Commission (Marie Skodowska-Curie Action Fellowship grant no. 661491 to E.G.) and an EMBO long-term Fellowship (grant no. ALTF 733-2016 to T.P.). S.G. is supported by the Peter and Traudl Engelhorn Foundation. Research in the Kubicek laboratory is supported by the Austrian Science Fund (grant no. FWF F4701) and the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant no. ERC-CoG-772437).
G.S.-F., S.K. and A.B. are founders and own shares of Solgate GmbH, an SLC-focused company. S. Sdelci and S.K. have filed patent application WO 2018/087401 A2 on synergistic combinations with BRD4 inhibitors. The other authors declare no competing interests.
Peer review information Nature Metabolism thanks Santosha Vardhana and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: George Caputa.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
a, RFP expression in REDS1, REDS15 and REDS17 clones with DMSO or 1 μM (+)-JQ1 treatment for 72 h. b, Representation of RFP insertion gene locus in REDS15 and REDS17 clones. Single RFP was inserted in chromosome 12, 410 bp (REDS15) or 673 bp (REDS17) upstream of STX2.
To generate the SLC knockout cells, we co-infected REDS cells with lentivirus-based Cas9-sgRNA expression cassettes (pLentiCRISPRv3-PuromycinR), pLentiGuide-BlasticidinR and pLentiGuide-NeomycinR carrying sgRen or sgSLC. The control and knockout cells were selected with 0.5 μg/ml puromycin, 20 μg/ml blasticidin and 250 μg/ml neomycin for 7 days.
Extended Data Fig. 3 Purine supplementation attenuates BRD4 inhibition phenotype in exogenous nucleosides limited condition.
a, Relative RFP intensity in REDS1 and REDS15 clones cultured in medium supplemented with 10% dialyzed serum (dFBS) over time. The log2 fold change of the RFP intensity was normalized with cells cultured in medium supplemented with 10% FBS. Mean ± s.d., n = 3 biologically independent samples. The p-value was calculated by unpaired t-tests. b, Relative RFP intensity in REDS15 cells after growing in medium supplemented with 10% dFBS for 10 days and further exogenously added with purine (adenosine and guanosine) or pyrimidine nucleosides (cytidine and thymidine) for 72 h. Mean ± s.d., n = 3 biologically independent samples.
a, Summary of the targeted pathways of metabolic compound library. b, Representative images of REDS15 cells with DMSO, 1 μM (+)-JQ1, 10 μM CPI-0610 or 10 μM 6-MP treatment for 72 h. Scale bar, 100 μm. c, RFP expression in REDS1 cells with indicated concentrations of 6-MP-related compounds treatment for 72 h. d, RFP expression in REDS1 and REDS15 cells with indicated concentrations of pelitrexol and lometrexol treatment for 72 h. e, RFP expression in REDS1 and REDS15 cells with indicated concentrations of pyrimidine metabolism inhibitors treatment for 72 h. f, Scheme of purine metabolism, enzymes participating in the cascade and the pathway intermediates.
Extended Data Fig. 5 Investigation of BRD4 and its related histone acetylation markers expression in REDS15 cells upon purine metabolism impairment.
a, Western blot analysis of BRD4 expression in chromatin-bound, nucleoplasm and cytoplasmic fractions after 10 μM pelitrexol or lometrexol treatment for 72 h. Lamin B1, GAPDH and histone H3 were markers for nuclear-chromatin, cytoplasm and chromatin-bound protein fractions. b,c, Western blot analysis of BRD4, H3K27ac and pan-H3ac expression in cells with 10 μM 6-MP treatment or bearing triple SLC knockout (SLC TKO, 12 days after sgRNA transduction) (b), and in cells with 10 μM pelitrexol or lometrexol treatment for 72 h (c). ns, non-specific band.
a, Principal component analysis on BRD4 ChIP-seq raw counts in cells with indicated treatments. Upper panel, with 3 replicates of individual treatment. Lower panel, with replicate number 3 in 6-MP treated group (6-MP_BRD4_IP_rep3) excluded. b, Heatmaps representing BRD4 binding enrichment for all ChIP-seq consensus peak regions (N = 24,140) in individual replicates. c, Aggregate coverage plots showing mean enrichment for the different ChIP-seq consensus peak regions in cells with 10 μM 6-MP or 1 μM (+)-JQ1 treatment or bearing triple SLC knockout (SLC TKO), with ±10 kb centred on the regions. d, Genome browser visualization of BRD4 binding at its representative target genes MYC and BCL-2 in cells with indicated treatments.
a,b, Heat map of relative transcriptional change (a) and Pearson correlation coefficient of gene expression (b) in REDS1 and REDS15 clones with triple SLC knockout (SLC TKO, 12 days after sgRNA transduction), 10 μM 6-MP or 1 μM (+)-JQ1 treatment for 72 h. The log2 fold change of gene expression was calculated relatively to sgRen or DMSO treated cells. c,d, GSEA of the downregulated genes from the merged RNA-seq results of REDS1 and REDS15 clones (c). The GSEA plots show downregulation of MYC and E2F target gene sets (d). e, RT–qPCR analysis of MYC expression by using two different MYC primer sets in REDS1, REDS15 and K562 cells. Mean ± s.d., n = 3 biologically independent samples. f, Heat map of relative transcriptional change of purine metabolism genes in REDS1 and REDS15 clones with 10 μM 6-MP or 1 μM (+)-JQ1 treatment for 72 h or with triple SLC knockout (SLC TKO, 12 days after sgRNA transduction).
Extended Data Fig. 8 Loss of BRD4 inhibition phenotype in REDS15 cells after SLC sgRNA transduction for 23 days.
a, RFP expression in cells with SLC knockout 23 days after sgRNA transduction. b, TIDE analysis of SLC sgRNA editing efficiency. c, Metabolite composition in cells with triple SLC knockout (SLC TKO) 23 days after sgRNA transduction. The log2 fold change of metabolites level was calculated relatively to sgRen cells. AA, amino acids; NT, nucleotides; NB, nucleobases; NS, nucleosides. d, Western blot analysis of BRD4 expression in chromatin-bound, nucleoplasm and cytoplasmic fractions. Lamin B1, GAPDH and histone H3 were markers for nuclear-chromatin, cytoplasm and chromatin-bound protein fractions. ns, non-specific band. e, The viability of triple SLC knockout (SLC TKO) day 12 and day 23 cells after lometrexol treatment for 72 h. Cell numbers were measured by CASY Cell Counter and Analyzer and normalized with the control sgRen day 12 or day 23 cells. Mean ± s.d., n = 3 biologically independent samples. f, Relative RFP intensity in sgRen or triple SLC knockout (SLC TKO) day 12 or 23 cells with lometrexol treatment for 72 h. The log2 fold change of the RFP intensity was normalized with sgRen cells with DMSO treatment. g, Heat map of the relative transcriptional change of genes in SLC28, SLC29 and SLC35 families in REDS15 triple SLC knockout day 12 and day 23 cells normalized with the respective controls sgRen day 12 and day 23 cells. h, Stable isotope labeled +1 adenine or +3 glycine tracing into nucleotides in sgRen or triple SLC knockout (SLC TKO) day 12 and day 23 cells. Mean ± s.d., n = 3 biologically independent samples. The p-value was calculated by unpaired t-tests.
Extended Data Fig. 9 Inhibition of nucleoside transport or de novo purine synthesis synergistically impairs leukemia cells growth with CPI-0610.
a,b, Dose-response matrix displaying the cell viability measured using CellTiter Glo (a) and CASY Cell Counter and Analyzer (b) of Jurkat E6.1, Raji and K562 cells treated with indicated concentrations of CPI-0610 or 6-MP, or in combination for 72 h.
Extended Data Fig. 10 Investigating the rescuing effect of nucleotide metabolites on BRD4 functionality.
a-c, Relative RFP expression in REDS1 and REDS15 cells co-treated with 100 μM nucleotide metabolites and 10 μM SLC29A4 inhibitor TC-T 6000 for 72 h (a), 10 nM dBET6 for 24 h (b) and 1 μM (+)-JQ1 for 72 h (c). The log2 fold change was normalized with DMSO treated cells. d, Western blot analysis of BRD4, c-MYC and BRD4-related histone acetylation markers expression in REDS15 cells co-treated with 100 μM nucleotide metabolites and 10 μM 6-MP or 1 μM (+)-JQ1 for 72 h. ns, non-specific band.
Scans of western blot image_Fig. 1f.
Scans of western blot image_Fig. 3b.
Scans of western blot image_Fig. 5a–c.
Scans of western blot image_Fig. 8b.
Scans of western blot image_Fig. 10d.
About this article
Cite this article
Li, KC., Girardi, E., Kartnig, F. et al. Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states. Nat Metab 3, 651–664 (2021). https://doi.org/10.1038/s42255-021-00386-8